Apr 05, 2012, 10.58 PM | Source: CNBC-TV18
Bio-pharma major Biocon on expansion mode.
Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.
Biocon stock price
On February 11, 2016, Biocon closed at Rs 442.90, down Rs 14.45, or 3.16 percent. The 52-week high of the share was Rs 544.00 and the 52-week low was Rs 396.50.
The company's trailing 12-month (TTM) EPS was at Rs 35.92 per share as per the quarter ended December 2015. The stock's price-to-earnings (P/E) ratio was 12.33. The latest book value of the company is Rs 129.18 per share. At current value, the price-to-book value of the company is 3.43.
Need $5 bn more to make biotech a $100 bn sector: Mazumdar-Shaw
She said to dominate in the field such as biotechn
Exempt life saving drugs from 'any levies': Mazumdar-Shaw
Recently, the Central Board of Excise and Customs
Short Biocon; buy Asian Paints, Pidilite: Rajat Bose
Rajat Bose of rajatkbose.com is of the view that o
US API import ban applies only to one drug: Biocon CMD
The US governmentâs decision to not allow ove
Buy HUL, Britannia; short BHEL, Reliance Power, Biocon: Gaba
Prakash Gaba of prakashgaba.com recommends going l
Buy Biocon ; target of Rs 650:Axis Securities
Axis Securities is bullish on Biocon and has recom
Budget 2016: Need FM to provide incentive to undertake R&D, says Mindtree
"I would anticipate the Budget to provide credit a
Jayshree Chemicals' vice president R C Kalani resigns
Jayshree Chemicals Ltd has informed BSE that Shri.